A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT
Condition: Multiple Sclerosis Interventions: Drug: Alemtuzumab GZ402673; Drug: Glatiramer acetate; Drug: Beta-Interferon; Drug: Methylprednisolone; Drug: Ranitidine; Drug: Ceterizine; Drug: Dexchlorpheniramine; Drug: Paracetamol; Drug: Acyclovir; Drug: Prednisolone Sponsor: Genzyme, a Sanofi Company Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 11, 2017 Category: Research Source Type: clinical trials